<bill session="117" type="h" number="7515" updated="2022-12-29T23:03:23Z">
  <state datetime="2022-04-14">REFERRED</state>
  <status>
    <introduced datetime="2022-04-14"/>
  </status>
  <introduced datetime="2022-04-14"/>
  <titles>
    <title type="display">Infectious Disease Therapies Research and Innovation Act of 2022</title>
    <title type="short" as="introduced">Infectious Disease Therapies Research and Innovation Act of 2022</title>
    <title type="official" as="introduced">To amend the Internal Revenue Code of 1986 to provide an exception from the passive loss rules for investments in specified medical research small business pass-thru entities.</title>
  </titles>
  <sponsor bioguide_id="K000376"/>
  <cosponsors>
    <cosponsor bioguide_id="B001260" joined="2022-04-14"/>
    <cosponsor bioguide_id="W000815" joined="2022-04-14"/>
  </cosponsors>
  <actions>
    <action datetime="2022-04-14">
      <text>Introduced in House</text>
    </action>
    <action datetime="2022-04-14" state="REFERRED">
      <text>Referred to the House Committee on Ways and Means.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSWM" name="House Ways and Means" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Taxation"/>
  </subjects>
  <amendments/>
  <summary date="2022-05-18T13:20:31Z" status="Introduced in House">Infectious Disease Therapies Research and Innovation Act of 2022

This bill exempts from the definition of passive activity, for purposes of the passive loss tax rules, any qualified medical research activity of a specified medical research small business pass-thru entity.

The bill defines specified medical research small business pass-thru entity as any domestic pass-thru entity if more than 80% of such entity's expenditures on research are paid or incurred in connection with qualified medical research activities and the gross receipts of such entity for the taxable year are less than $1 million.</summary>
</bill>
